Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4

Alimentary Pharmacology and Therapeutics

Volumn 47, Issue 5, 2018, Pages 674-679

  El Khayat, H ^a   Fouad, Y ^b   Mohamed, H I ^b   El Amin, H ^c   Kamal, E M ^b   Maher, M ^d   Risk, A ^e  

^a THEODOR BILHARZ RESEARCH INSTITUTE   (Egypt)

^b MINIA UNIVERSITY   (Egypt)

^c ASSIUT UNIVERSITY   (Egypt)

^d AIN SHAMS UNIVERSITY   (Egypt)

^e CAIRO UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

DACLATASVIR; RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT; BMS-790052; IMIDAZOLE DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; ASCITES; CHRONIC HEPATITIS C; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEPATIC ENCEPHALOPATHY; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; HYPERBILIRUBINEMIA; INFORMED CONSENT; INTENTION TO TREAT ANALYSIS; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PHOTOSENSITIVITY; POPULATION RESEARCH; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; DRUG EFFECT; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C; MIDDLE AGED; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HUMANS; IMIDAZOLES; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RIBAVIRIN; SOFOSBUVIR; SUSTAINED VIROLOGIC RESPONSE;

EID: 85041690960     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.14482     Document Type: Article

References (19)

1. Backus LI, Boothroyd DB, Phillips BR, et al. A sustained virologic response reduces risk of all-cause mortality patients with hepatitis C. Clin Gastroenterol Hepatol. 2011;9:509-516.
2. Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med. 2013;19:850-858.
3. Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010;465:96-100.
4. Asselah T. Sofosbuvir for the treatment of hepatitis C virus. Expert Opin Pharmacother 2013;15:121-130.
5. Panel AIHG. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932-954.
6. Estrabaud E, Vidaud M, Marcellin P, Asselah T. Genomics and HCV infection: progression of fibrosis and treatment response. J Hepatol. 2012;57:1110-1125.
7. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289-293.
8. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63:199-236.
9. Hassanein T, Sims KD, Bennett M, et al. A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection. J Hepatol. 2015;62:1204-1206.
10. Wyles D, Ruane PJ, Sulkowski M, et al. (K Sherman presenting). Daclatasvir plus Sofosbuvir for Treatment of HCV Genotypes 1-4 in HIV-HCV Coinfection: The ALLY-2 Study. Digestive Disease Week 2015. 6-19. Abstract 901d.
11. Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplant recurrence. Hepatology. 2016;63:1493-1505.
12. Doss W, Shiha G, Hassany M, et al. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J Hepatol. 2015;63:581-585.
13. Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61:1127-1135.
14. Pellicelli AM, Montalbano M, Lionetti R, et al. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late. Dig Liver Dis. 2014;46:923-927.
15. Aqel BA, Watt KD, Pungpapong S, et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis c genotype 1 in patients with cirrhosis. Hepatology 2015;62:1005-1012.
16. Leroy V, Angus P, Bronowicki JP, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3 +). Hepatology. 2016;63:1430-1441.
17. Hezode C, de Ledinghen V, Fontaine H, et al. Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV genotype 3 infection: interim analysis of a French multicenter compassionate use program (abstract). Hepatology. 2015;62(Suppl 1):314A.
18. Welzel TM, Petersen J, Herzer K, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut 2016;65:1861-1870.
19. Curry MP, O'Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373:2618-2628.